SuperworthProtalix BioTherapeutics shares outstanding PLX
Diluted shares outstanding, averaged over each quarter, from 2011.
- Latest quarter, to Jun 30, 2026
- 82.6M
- On a year earlier
- +1.6%
- more shares
Protalix BioTherapeutics had 82.6M diluted shares outstanding on average in Q2 FY26, the quarter to Jun 30, 2026.
That is 1.6% more than a year earlier, so each share owns a little less of the company.
Shares outstanding over time
Fiscal year by fiscal year
| Fiscal year | Shares, fourth quarter | Change |
|---|---|---|
| FY2025 | 79.5M | +1% |
| FY2024 | 78.8M | +9% |
| FY2023 | 72.6M | +42% |
| FY2022 | 51.1M | +13% |
| FY2021 | 45.3M | +36% |
| FY2020 | 33.3M | +124% |
| FY2019 | 14.8M | +0% |
| FY2018 | 14.8M | +6% |
| FY2017 | 14M | +31% |
| FY2016 | 10.6M | +7% |
| FY2015 | 9.9M | +6% |
| FY2014 | 9.3M | +1% |
| FY2013 | 9.3M | +1% |
| FY2012 | 9.2M | +7% |
| FY2011 | 8.6M | n/a |
Each fiscal year is the twelve months to its fourth quarter, shown as the fourth quarter's average share count.
Quarter by quarter
| Quarter | Ended | Shares outstanding | On a year earlier |
|---|---|---|---|
| Q2 FY26 | 82.6M | +2% | |
| Q1 FY26 | 83M | +8% | |
| Q4 FY25 | 79.5M | +1% | |
| Q3 FY25 | 80.8M | −0% | |
| Q2 FY25 | 81.3M | +11% | |
| Q1 FY25 | 76.6M | +5% | |
| Q4 FY24 | 78.8M | +9% | |
| Q3 FY24 | 81.2M | −3% | |
| Q2 FY24 | 73.3M | −12% | |
| Q1 FY24 | 73M | +27% | |
| Q4 FY23 | 72.6M | +42% | |
| Q3 FY23 | 83.8M | +69% |
What the shares outstanding tells you
Diluted shares outstanding, averaged over the period. Fewer shares means each one owns more of the company.
A falling count usually means buybacks. A rising one means stock pay, acquisitions paid in shares or new shares sold.
More on Protalix BioTherapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.